{Reference Type}: Journal Article
{Title}: The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies.
{Author}: Pieroni M;Ciabatti M;Graziani F;Camporeale A;Saletti E;Lillo R;Figliozzi S;Bolognese L;
{Journal}: Rev Cardiovasc Med
{Volume}: 23
{Issue}: 6
{Year}: 2022 Jun
{Factor}: 4.43
{DOI}: 10.31083/j.rcm2306196
{Abstract}: In patients with Fabry disease (FD), cardiovascular involvement is the main cause of death and reduction of quality of life. Left ventricular hypertrophy mimicking hypertrophic cardiomyopathy is the main feature of FD cardiac involvement although glycolipid storage occurs in all cardiac cellular types. Accumulation of lysosomal globotriasylceramide represents the main mechanism of cardiac damage in early stages, but secondary pathways of cellular and tissue damage, triggered by lysosomal storage, and including altered energy production, inflammation and cell death, contribute to cardiac damage and disease progression. These mechanisms appear prominent in more advanced stages, hampering and reducing the efficacy of FD-specific treatments. Therefore, additional cardiovascular therapies are important to manage cardiovascular symptoms and reduce cardiovascular events. Although new therapies targeting lysosomal storage are in development, a better definition and comprehension of the complex pathophysiology of cardiac damage in FD, may lead to identify new therapeutic targets beyond storage and new therapeutic strategies.